The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Highlights from the Tandem Meetings: new promising CAR-T constructs
Manali Kamdar, MD, University of Colorado Cancer Center, Aurora, CO, shares her highlights from the 2022 Tandem Meetings, discussing updates in CAR-T constructs for both non-Hodgkin and Hodgkin lymphoma, as well as trends in the use of autologous transplantation and CAR-T therapy. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Disclosures
Research Support/Funding: TG Therapeutics, Genentech, Novartis
Consultancy: AbbVie, AstraZeneca, Celgene/ Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics, Beigene, Genentech, Impact bio
Speaker’s bureau: SeaGen
DMC: Celgene , Genentech
